PL4023222T3 - Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome - Google Patents

Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome

Info

Publication number: PL4023222T3
Authority: PL; Poland
Prior art keywords: syndrome; treatment; glutamate receptor; metabotropic glutamate; receptor activator
Prior art date: 2015-09-08

Application number

PL22156141.8T

Other languages

Polish (pl)

Inventor

Hakon Hakonarson

Charlly Kao

Original Assignee

The Children's Hospital Of Philadelphia

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-09-08

Filing date

2016-09-07

Publication date

2025-03-24

2016-09-07 Application filed by The Children's Hospital Of Philadelphia filed Critical The Children's Hospital Of Philadelphia

2025-03-24 Publication of PL4023222T3 publication Critical patent/PL4023222T3/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Immunology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

PL22156141.8T 2015-09-08 2016-09-07 Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome PL4023222T3 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US201562215673P	2015-09-08	2015-09-08
US201562215628P	2015-09-08	2015-09-08
US201562215633P	2015-09-08	2015-09-08
US201562215636P	2015-09-08	2015-09-08

Publications (1)

Publication Number	Publication Date
PL4023222T3 true PL4023222T3 (en)	2025-03-24

Family

ID=56943962

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL21170586.8T PL3922249T3 (en)	2015-09-08	2016-09-07	Diagnosing and treating anxiety disorder
PL21201628.1T PL3977996T3 (en)	2015-09-08	2016-09-07	Treating tourette syndrome
PL22156141.8T PL4023222T3 (en)	2015-09-08	2016-09-07	Nonselective metabotropic glutamate receptor activator for treatment of 22q syndrome
PL21201653.9T PL3964213T3 (en)	2015-09-08	2016-09-07	Treatment of conduct disorder

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL21170586.8T PL3922249T3 (en)	2015-09-08	2016-09-07	Diagnosing and treating anxiety disorder
PL21201628.1T PL3977996T3 (en)	2015-09-08	2016-09-07	Treating tourette syndrome

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL21201653.9T PL3964213T3 (en)	2015-09-08	2016-09-07	Treatment of conduct disorder

Country Status (12)

Country	Link
US (14)	US11179378B2 (en)
EP (12)	EP3922249B1 (en)
JP (11)	JP7281280B2 (en)
CN (7)	CN108348517B (en)
AU (10)	AU2016318785B2 (en)
CA (5)	CA3288371A1 (en)
DK (4)	DK3347014T3 (en)
ES (8)	ES3009523T3 (en)
IL (13)	IL290993B2 (en)
PL (4)	PL3922249T3 (en)
SG (1)	SG10202012842SA (en)
WO (4)	WO2017044497A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2609220B1 (en)	2010-08-24	2018-06-27	The Children's Hospital of Philadelphia	Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same
PL3922249T3 (en) *	2015-09-08	2024-07-29	The Children's Hospital Of Philadelphia	Diagnosing and treating anxiety disorder
US20200143922A1 (en) *	2016-06-03	2020-05-07	Yale University	Methods and apparatus for predicting depression treatment outcomes
CA3035971A1 (en) *	2016-09-07	2018-03-15	The Children's Hospital Of Philadelphia	Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
WO2018195184A1 (en) *	2017-04-19	2018-10-25	Aevi Genomics Medicine, Inc.	Methods of diagnosing and treating adhd in biomarker positive subjects
WO2018209328A1 (en) *	2017-05-11	2018-11-15	Miwa Julie M	Compositions and methods for treating lynx2 disorders
CN107483425B (en) *	2017-08-08	2020-12-18	北京盛华安信息技术有限公司	Composite attack detection method based on attack chain
AU2019209870B2 (en)	2018-01-18	2024-06-13	The Children's Hospital Of Philadelphia	Fasoracetam crystalline forms
US11608324B2 (en) *	2018-01-18	2023-03-21	The Children's Hospital Of Philadelphia	Solid forms of fasoracetam
KR102250063B1 (en) *	2019-06-14	2021-05-12	한국생명공학연구원	Method for identifying causative genes of tourette syndrome
CN110955751A (en) *	2019-11-13	2020-04-03	广州供电局有限公司	Method, device and system for removing duplication of work ticket text and computer storage medium
MX2023003258A (en) *	2020-09-21	2023-05-08	Reveragen Biopharma Inc	TREATMENT OF NF-ÎºB-MEDIATED DISEASE.
WO2022065518A1 (en) *	2020-09-23	2022-03-31	国立大学法人京都大学	Neurite outgrowth promoter
KR20240112047A (en) *	2023-01-11	2024-07-18	차의과학대학교 산학협력단	A Biomarker For Detection of Anxiety Disorder
CN117594119B (en) *	2024-01-17	2024-05-10	北京大学第六医院	Device for predicting the efficacy of paroxetine or a pharmaceutically acceptable salt thereof for patients suffering from depression or anxiety

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995003801A1 (en) *	1993-07-28	1995-02-09	Nippon Shinyaku Co., Ltd.	Antidepressant
EP1047436B1 (en) *	1998-01-13	2009-10-21	Synchroneuron, LLC	N-acetylhomotaurinates for use in treating hyperkinesias
JP2004523557A (en) *	2001-02-23	2004-08-05	ジョンズ・ホプキンス・ユニバーシティ	Treatment of tics, tremors, and related disorders
DE10119330A1 (en) *	2001-04-19	2002-10-24	Basf Ag	Preparation of an aqueous polymer dispersion by radical emulsion polymerization useful in the pharmaceutical and cosmetic industries with decreased coagulant content and decreased soiling of the polymerization vessel
WO2003054167A2 (en)	2001-12-20	2003-07-03	Merck & Co., Inc.	Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
JP2007530591A (en)	2004-03-25	2007-11-01	スミスクライン・ビーチャム・コーポレイション	Use of NK3 antagonists to treat bipolar disorder
CA2643199A1 (en)	2006-03-08	2007-09-13	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) *	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
TW200819458A (en)	2006-06-23	2008-05-01	Merz Pharma Gmbh & Co Kgaa	Metabotropic glutamate receptor modulators
CA2676090A1 (en)	2007-02-06	2008-10-02	Genizon Biosciences Inc.	Genemap of the human genes associated with adhd
WO2008136988A2 (en)	2007-04-30	2008-11-13	The Ohio State University Research Foundation	Polymorphisms in genes affecting cyp2c9-related disorders and uses thereof
US20090176740A1 (en)	2007-11-30	2009-07-09	Phillips Ii Dauglas James	Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
AU2009217278B2 (en)	2008-02-20	2015-08-20	The Children's Hospital Of Philadelphia	Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
WO2010057132A1 (en)	2008-11-14	2010-05-20	The Children's Hospital Of Philadelphia	Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same
US20110311512A1 (en)	2008-11-14	2011-12-22	Hakon Hakonarson	Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
EP2470527A4 (en)	2009-08-20	2013-02-27	Merck Sharp & Dohme	BENZOTRIAZOLE D ETHER DERIVATIVES
US8714471B2 (en) *	2010-07-29	2014-05-06	Brady Worldwide, Inc.	Friction core brake
EP2609220B1 (en)	2010-08-24	2018-06-27	The Children's Hospital of Philadelphia	Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same
US20130225623A1 (en) *	2010-10-27	2013-08-29	Mount Sinai School Of Medicine	Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists
WO2013006857A1 (en)	2011-07-07	2013-01-10	The Children's Hospital Of Philadelphia	Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatment of autism
US20130143867A1 (en) *	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013305580A1 (en) *	2012-08-23	2015-04-09	Stuart L. Weg	Anxiolytic composition, formulation and method of use
US9346239B2 (en)	2012-09-26	2016-05-24	Eastman Kodak Company	Method for providing patterns of functional materials
WO2014152965A2 (en)	2013-03-14	2014-09-25	The Children's Hospital Of Philadelphia	Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets
SG11201609832XA (en)	2014-05-30	2016-12-29	Philadelphia Children Hospital	Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism
US11219617B2 (en)	2014-05-30	2022-01-11	The Children's Hospital Of Philadelphia	Methods of diagnosing and treating autism
KR102232583B1 (en)	2015-01-08	2021-03-26	삼성전자주식회사	Electronic apparatus and web representation method thereof
WO2016205348A1 (en)	2015-06-15	2016-12-22	The Children's Hospital Of Philadelphia	Methods of diagnosing and treating autism
PL3922249T3 (en)	2015-09-08	2024-07-29	The Children's Hospital Of Philadelphia	Diagnosing and treating anxiety disorder

2016
- 2016-09-07 PL PL21170586.8T patent/PL3922249T3/en unknown
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/en active Active
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/en active Pending
- 2016-09-07 ES ES22156141T patent/ES3009523T3/en active Active
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en not_active Ceased
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/en active Pending
- 2016-09-07 CA CA3288371A patent/CA3288371A1/en active Pending
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/en active Active
- 2016-09-07 IL IL319574A patent/IL319574A/en unknown
- 2016-09-07 ES ES21201628T patent/ES2980894T3/en active Active
- 2016-09-07 CA CA2997188A patent/CA2997188C/en active Active
- 2016-09-07 IL IL316004A patent/IL316004A/en unknown
- 2016-09-07 ES ES16767112T patent/ES2909329T3/en active Active
- 2016-09-07 IL IL290985A patent/IL290985B2/en unknown
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/en active
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 ES ES21201653T patent/ES2981632T3/en active Active
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 ES ES16767114T patent/ES2897953T3/en active Active
- 2016-09-07 EP EP24211831.3A patent/EP4491238A3/en active Pending
- 2016-09-07 PL PL21201628.1T patent/PL3977996T3/en unknown
- 2016-09-07 CA CA2997191A patent/CA2997191C/en active Active
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 ES ES16771034T patent/ES2876898T3/en active Active
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/en active Active
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 EP EP24162567.2A patent/EP4410289A1/en not_active Withdrawn
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/en active
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/en active Active
- 2016-09-07 EP EP22156141.8A patent/EP4023222B1/en active Active
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/en active Pending
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en not_active Ceased
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/en active
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/en active
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/en active Active
- 2016-09-07 PL PL22156141.8T patent/PL4023222T3/en unknown
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en not_active Ceased
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/en active Pending
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 EP EP24162566.4A patent/EP4410288B1/en active Active
- 2016-09-07 IL IL303605A patent/IL303605B2/en unknown
- 2016-09-07 IL IL290994A patent/IL290994B2/en unknown
- 2016-09-07 ES ES21170586T patent/ES2976071T3/en active Active
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/en active Pending
- 2016-09-07 ES ES16767115T patent/ES2898932T3/en active Active
- 2016-09-07 IL IL316145A patent/IL316145A/en unknown
- 2016-09-07 EP EP24153857.8A patent/EP4342493A3/en active Pending
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/en active Pending
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en not_active Ceased
- 2016-09-07 IL IL300474A patent/IL300474B2/en unknown
- 2016-09-07 PL PL21201653.9T patent/PL3964213T3/en unknown
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
2018
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US12121514B2/en active Active
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/en active Pending
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en not_active Abandoned
- 2022-05-05 AU AU2022203039A patent/AU2022203039B2/en active Active
- 2022-06-20 AU AU2022204324A patent/AU2022204324B2/en active Active
- 2022-06-21 AU AU2022204355A patent/AU2022204355B2/en active Active
- 2022-07-11 AU AU2022205142A patent/AU2022205142B2/en active Active
- 2022-09-29 JP JP2022155714A patent/JP7532465B2/en active Active
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/en not_active Withdrawn
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/en not_active Withdrawn
2023
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
2024
- 2024-07-31 JP JP2024125021A patent/JP2024164036A/en active Pending
- 2024-09-18 US US18/888,877 patent/US20250120962A1/en active Pending
- 2024-10-23 US US18/924,522 patent/US20250127771A1/en active Pending
- 2024-11-11 AU AU2024259882A patent/AU2024259882A1/en active Pending
- 2024-11-11 AU AU2024259877A patent/AU2024259877A1/en active Pending
2025
- 2025-08-07 JP JP2025131955A patent/JP2025179063A/en active Pending
- 2025-08-07 JP JP2025131952A patent/JP2025183206A/en active Pending

Also Published As

Publication number	Publication date
JP2022078104A (en)	2022-05-24
JP2018526398A (en)	2018-09-13
US20170087140A1 (en)	2017-03-30
IL257744B (en)	2022-04-01
AU2016318785B2 (en)	2022-04-14
AU2016318786A1 (en)	2018-04-12
IL316004A (en)	2024-11-01
IL300474A (en)	2023-04-01
CA2997187C (en)	2024-02-20
US20200306237A1 (en)	2020-10-01
EP3347015B1 (en)	2021-10-20
CA2997191A1 (en)	2017-03-16
IL300474B2 (en)	2025-08-01
EP3964213B1 (en)	2024-03-13
ES2897953T3 (en)	2022-03-03
IL290985A (en)	2022-05-01
HK1258447A1 (en)	2019-11-15
CA3288371A1 (en)	2026-03-02
CA2997191C (en)	2025-06-17
JP2025179063A (en)	2025-12-09
EP3977996B1 (en)	2024-03-13
AU2022205142A1 (en)	2022-07-28
JP2025183206A (en)	2025-12-16
IL316145A (en)	2024-12-01
EP4410288B1 (en)	2025-12-10
PL3964213T3 (en)	2024-07-08
EP3347015A1 (en)	2018-07-18
CN108601776A (en)	2018-09-28
IL303605A (en)	2023-08-01
AU2016318780A1 (en)	2018-04-12
IL300474B1 (en)	2025-04-01
HK1258446A1 (en)	2019-11-15
ES2980894T3 (en)	2024-10-03
IL290985B1 (en)	2024-11-01
EP4023222A1 (en)	2022-07-06
IL257785A (en)	2018-06-28
JP2018526396A (en)	2018-09-13
US11179378B2 (en)	2021-11-23
AU2024259882A1 (en)	2024-11-28
EP3347013B1 (en)	2022-02-16
IL290992B2 (en)	2023-07-01
IL290993B2 (en)	2023-11-01
US20170105985A1 (en)	2017-04-20
AU2022204324A1 (en)	2022-07-07
EP4342493A2 (en)	2024-03-27
ES2981632T3 (en)	2024-10-09
IL257747A (en)	2018-06-28
AU2016318780B2 (en)	2022-04-07
JP2023011558A (en)	2023-01-24
IL290992A (en)	2022-05-01
JP2018526395A (en)	2018-09-13
IL290994B2 (en)	2025-03-01
IL303605B2 (en)	2026-01-01
DK3347014T3 (en)	2021-12-06
AU2016318786B2 (en)	2022-04-07
EP3347014A1 (en)	2018-07-18
IL290985B2 (en)	2025-03-01
US11298347B2 (en)	2022-04-12
IL290992B1 (en)	2023-03-01
US10869861B2 (en)	2020-12-22
PL3922249T3 (en)	2024-07-29
US11806341B2 (en)	2023-11-07
EP3977996A1 (en)	2022-04-06
EP4410288A1 (en)	2024-08-07
EP3347016A1 (en)	2018-07-18
CN116919961A (en)	2023-10-24
US12121514B2 (en)	2024-10-22
US20250120962A1 (en)	2025-04-17
IL290993B1 (en)	2023-07-01
IL257747B (en)	2022-04-01
CA2997187A1 (en)	2017-03-16
AU2016318775A1 (en)	2018-04-12
AU2022205142B2 (en)	2024-08-29
CN108348518A (en)	2018-07-31
CA2997188C (en)	2026-02-24
EP4491238A2 (en)	2025-01-15
ES2876898T3 (en)	2021-11-15
EP4410289A1 (en)	2024-08-07
IL290994B1 (en)	2024-11-01
US20240100036A1 (en)	2024-03-28
HK1258448A1 (en)	2019-11-15
US9884057B2 (en)	2018-02-06
JP2023051937A (en)	2023-04-11
JP2018526394A (en)	2018-09-13
HK1258373A1 (en)	2019-11-08
EP4342493A3 (en)	2024-07-03
IL290994A (en)	2022-05-01
AU2022203039A1 (en)	2022-05-26
AU2024259877A1 (en)	2024-11-28
JP2024164036A (en)	2024-11-26
DK3347016T3 (en)	2021-07-12
EP3347013A1 (en)	2018-07-18
EP4023222B1 (en)	2024-12-18
JP7281280B2 (en)	2023-05-25
CN108348517A (en)	2018-07-31
CN108348517B (en)	2021-11-05
US20210205288A1 (en)	2021-07-08
AU2016318785A1 (en)	2018-04-12
CA2997188A1 (en)	2017-03-16
WO2017044503A1 (en)	2017-03-16
US11173153B2 (en)	2021-11-16
WO2017044502A1 (en)	2017-03-16
ES2898932T3 (en)	2022-03-09
EP3347014B1 (en)	2021-10-20
US11806340B2 (en)	2023-11-07
WO2017044497A1 (en)	2017-03-16
CA3225374A1 (en)	2017-03-16
IL319574A (en)	2025-05-01
AU2022204324B2 (en)	2024-08-29
JP2023036671A (en)	2023-03-14
US20240075022A1 (en)	2024-03-07
US20170087141A1 (en)	2017-03-30
US20220117954A1 (en)	2022-04-21
US20170087139A1 (en)	2017-03-30
AU2022204355A1 (en)	2022-07-14
ES2909329T3 (en)	2022-05-06
JP7152306B2 (en)	2022-10-12
EP3347016B1 (en)	2021-04-28
PL3977996T3 (en)	2024-07-01
JP7281279B2 (en)	2023-05-25
AU2016318775B2 (en)	2022-02-10
DK3347013T3 (en)	2022-04-04
AU2022203039B2 (en)	2024-08-22
SG10202012842SA (en)	2021-01-28
US20220117953A1 (en)	2022-04-21
IL257746A (en)	2018-06-28
CA2997189A1 (en)	2017-03-16
CN108495630A (en)	2018-09-04
IL257744A (en)	2018-06-28
IL257746B (en)	2022-04-01
JP7532465B2 (en)	2024-08-13
DK3347015T3 (en)	2021-12-06
US20250127771A1 (en)	2025-04-24
EP3922249A1 (en)	2021-12-15
EP4491238A3 (en)	2025-07-09
JP7027308B2 (en)	2022-03-01
WO2017044491A1 (en)	2017-03-16
IL303605B1 (en)	2025-09-01
AU2022204355B2 (en)	2024-08-29
ES2976071T3 (en)	2024-07-22
ES3009523T3 (en)	2025-03-27
CN115919852A (en)	2023-04-07
CN116919962A (en)	2023-10-24
US20180110767A1 (en)	2018-04-26
EP3964213A1 (en)	2022-03-09
US20220296582A1 (en)	2022-09-22
IL290993A (en)	2022-05-01
EP3922249B1 (en)	2024-02-28
IL257785B (en)	2022-04-01

Publication	Publication Date	Title
IL290992B1 (en)	2023-03-01	Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
IL255096B (en)	2020-01-30	Ethynyl derivatives as metabotropic glutamate receptor modulators
GB2542881B (en)	2020-01-01	Crystal forms of ß-nicotinamide mononucleotide
IL252417A0 (en)	2017-07-31	Methods of modulating drug plasma levels using erythrohydroxybupropion
IL252839A0 (en)	2017-08-31	Treatment of pemphigus
DK3386484T3 (en)	2022-07-04	COMPOSITIONS AND METHODS OF DELIVERING THERAPY PRODUCTS
PT3797742T (en)	2025-03-10	Apparatus for suprachoroidal administration of therapeutic agent
ZA201800449B (en)	2019-07-31	Targeted conjugates of ksp inhibitors
AU2015243092A1 (en)	2016-05-12	Biceps tenodesis anchor implants
SG11201708034SA (en)	2017-10-30	Methods of administering glutaminase inhibitors
EP3191185A4 (en)	2018-03-21	Device for targeted treatment of dermastoses
IL249502B (en)	2020-09-30	Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
ZA201702403B (en)	2018-08-29	Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders
EP3558301A4 (en)	2020-07-29	Methods of treating glioblastoma multiforme using ibudilast
PT3107900T (en)	2018-01-08	5-benzylisoquinoleine derivatives for the treatment of cardiovascular diseases
IL255420A0 (en)	2017-12-31	Selective modulators of the activity of the gpr55 receptor: chromenopyrazole derivatives
IL251230A0 (en)	2017-05-29	Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group iimetabotropic glutamate receptors
IL250287B (en)	2020-02-27	Chromone oxime derivative and its use as allosteric modulator of metabotropic glutamate receptors
PL3128840T3 (en)	2023-01-09	FRUCTO-OLIGOSACCHARIDES FRUCTOOLIGOSACCHARIDS, METHOD OF ADMINISTRATION AND ITS APPLICATION
IL248695A0 (en)	2017-01-31	Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
HUP1400123A2 (en)	2015-09-28	Salts of sunitinib, their polymorphs and pharmaceutical compositions comprising them
HK1242360A1 (en)	2018-06-22	Sphingosine-1-phospate receptor modulators for treatment of cardiopulmonary disorders